Lou Gehrig's Disease News and Research

RSS
Lou Gehrig's Disease or Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder characterized by progressive degeneration of motor neuron cells in the spinal cord and brain, which ultimately results in paralysis and death. The disease takes its less-scientific name from Lou Gehrig, a baseball player with the New York Yankees in the late 1920s and 1930s, who was forced to retire in 1939 as a result of the loss of motor control caused by the disease.

In 1991, a team of researchers linked familial ALS to chromosome 21. Two years later, the SOD1 gene was identified as being associated with many cases of familial ALS. The enzyme coded for by SOD1 carries out a very important function in cells: it removes dangerous superoxide radicals by converting them into non-harmful substances. Defects in the action of this enzyme mean that the superoxide radicals attack cells from the inside, causing their death. Several different mutations in this enzyme all result in ALS, making the exact molecular cause of the disease difficult to ascertain.

Recent research has suggested that treatment with drugs called antioxidants may benefit ALS patients. However, since the molecular genetics of the disease are still unclear, a significant amount of research is still required to design other promising treatments for ALS.
Unexpected findings could lead to new therapeutic intervention for ALS

Unexpected findings could lead to new therapeutic intervention for ALS

Collaborative research uncovers underlying rules that, when broken, contribute to ALS

Collaborative research uncovers underlying rules that, when broken, contribute to ALS

AI Therapeutics reports considerable progress on LAM-001 and LAM-004 clinical trials

AI Therapeutics reports considerable progress on LAM-001 and LAM-004 clinical trials

A new kind of testing for patients with Parkinson's disease

A new kind of testing for patients with Parkinson's disease

Magnetic nano-sized disks could restore function for Lou Gehrig’s disease patients

Magnetic nano-sized disks could restore function for Lou Gehrig’s disease patients

ALS patients with commonly inherited genetic variation may experience more severe symptoms

ALS patients with commonly inherited genetic variation may experience more severe symptoms

Northwestern scientists receive $3.1 million grant to investigate drug therapies for ALS

Northwestern scientists receive $3.1 million grant to investigate drug therapies for ALS

Novel robotic neck brace could improve quality of life for ALS patients

Novel robotic neck brace could improve quality of life for ALS patients

Prion disease in mice treated successfully with antisense oligonucleotides

Prion disease in mice treated successfully with antisense oligonucleotides

Intestinal microbes may affect course of amyotrophic lateral sclerosis

Intestinal microbes may affect course of amyotrophic lateral sclerosis

Researchers explain how 'viral' agents of neurological diseases ended up in our DNA

Researchers explain how 'viral' agents of neurological diseases ended up in our DNA

Copper compound with potential as therapy for ALS shows further promise

Copper compound with potential as therapy for ALS shows further promise

Researchers determine atomic interactions that stabilize phase-changing proteins

Researchers determine atomic interactions that stabilize phase-changing proteins

Protein Clumps In ALS Neurons Provide Potential Target For New Therapies

Protein Clumps In ALS Neurons Provide Potential Target For New Therapies

Anti-aging protein hormone Klotho shown to be neuroprotective in ALS model

Anti-aging protein hormone Klotho shown to be neuroprotective in ALS model

Study finds link between high BMI and lower risk of ALS

Study finds link between high BMI and lower risk of ALS

UTA professor awarded $2.88 million for novel research on Lou Gehrig's disease

UTA professor awarded $2.88 million for novel research on Lou Gehrig's disease

Human iPSCs make more tiny 'cargo packets' to deliver cellular aging therapies

Human iPSCs make more tiny 'cargo packets' to deliver cellular aging therapies

Researchers uncover potential clue to halt destruction of nerve cells in people with ALS

Researchers uncover potential clue to halt destruction of nerve cells in people with ALS

Biochemical switches could be triggered to treat pathology of IBM, ALS and FTD

Biochemical switches could be triggered to treat pathology of IBM, ALS and FTD

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.